35795-16-5

Basic information

• Product Name: Trimazosin
• Synonyms: Trimazosin;4-(4-Amino-6,7,8-trimethoxyquinazolin-2-yl)-1-piperazinecarboxylic acid 2-hydroxy-2-methylpropyl ester;2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinqzolinyl)-1-piperazinecar boxylate;4-(4-Amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2- methylpropyl ester;C005185;Cp 19,106;Cp-19,106;2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
• CAS NO: 35795-16-5
• Molecular Formula: C₂₀H₂₉N₅O₆
• Molecular Weight: 435.47
• EINECS: 252-732-7
• Mol File: 35795-16-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 158-159°
• Boiling Point: 648.2°Cat760mmHg
• Flash Point: 345.8°C
• Appearance: /
• Density: 1.31g/cm³
• Vapor Pressure: 1.09E-17mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: Trimazosin(CAS DataBase Reference)
• NIST Chemistry Reference: Trimazosin(35795-16-5)
• EPA Substance Registry System: Trimazosin(35795-16-5)

Safety Data

• Hazardous Substances Data: 35795-16-5(Hazardous Substances Data)

Usage

Uses

Antihypertensive.

InChI:InChI=1/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives

6,7-Dimethoxy-4-amino-2-(4-substituted piperazin-1-yl)-quinazolines and 6,7,8-trimethoxy-4-amino-2-(4-substituted piperazin-1-yl)quinazolines are produced by either: (1) reaction of the appropriate 4,5-dimethoxy substituted or 3,4,5-trimethoxy substituted 2-aminobenzonitrile with certain 1,4-disubstituted piperazines; or (2) reaction of the appropriate 4,5-dimethoxy substituted or 3,4,5-trimethoxy substituted 2-aminobenzamidine with the same 1,4-disubstituted piperazines. The products are known hypotensive agents.